Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights

Core Viewpoint - A class action securities lawsuit has been filed against Agenus Inc. for alleged securities fraud affecting investors between January 23, 2023, and July 17, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Agenus made false statements regarding the effectiveness of its immuno-oncology combination therapy involving botensilimab and balstilimab, which were overstated [2]. - The complaint alleges that the clinical results and regulatory prospects of botensilimab and balstilimab were misrepresented, leading to materially false and misleading public statements [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until November 5, 2024, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [2]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [2]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [3].